tbuckley/cabot-search huggingface dataset:
Emerging potentials of Fe‐based nanomaterials for chiral sensing and imaging
Authors: Njemuwa Nwaji, Juyong Gwak, My‐Chi Nguyen, Huu‐Quang Nguyen, Hyojin Kang, Youngeun Choi, Youngmi Kim, Hongxia Chen, Jaebeom Lee
Journal: Medicinal Research Reviews (2023)

Abstract Fe‐based nanostructures have possessed promising properties that make it suitable for chiral sensing and imaging applications owing to their ultra‐small size, non‐toxicity, biocompatibility, excellent photostability, tunable fluorescence, and water solubility. This review summarizes the recent research progress in the field of Fe‐based nanostructures and places special emphases on their applications in chiral sensing and imaging. The synthetic strategies to prepare the targeted Fe‐based structures were also introduced. The chiral sensing and imaging applications of the nanostructures are discussed in details.
Risk of anaphylaxis after <scp>COVID</scp>‐19 vaccination in South Korea: A nationwide <scp>self‐controlled</scp> case series analysis
Authors: Dongwon Yoon, Ju Hwan Kim, Han Eol Jeong, Hwa Yeon Ko, Sung‐Ryeol Kim, Ju‐Young Shin
Journal: Allergy (2023)

The datasets are not publicly available. If you have any questions about this study, please contact the corresponding authors ([email protected]; [email protected]). Appendix S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer
Authors: Christian Rolfo, Alessandro Russo
Journal: Clinical Cancer Research (2023)

Summary Chemo-immunotherapy is the current standard of care for extensive-stage small cell lung cancer, but predictive biomarkers are lacking. In a recent article, the authors report the predictive role of programmed death ligand-1 expression and tissue tumor mutational burden on durvalumab ± tremelimumab + platinum-etoposide efficacy. See related article by Paz-Ares et al., p. 824
Impact of anaemia and iron deficiency on outcomes in cardiogenic shock complicating acute myocardial infarction
Authors: Danilo Obradovic, Goran Loncar, Uwe Zeymer, Janine Pöss, Hans‐Josef Feistritzer, Anne Freund, Alexander Jobs, Georg Fuernau, Steffen Desch, Uta Ceglarek, Berend Isermann, Stephan von Haehling, Stefan D. Anker, Petra Büttner, Holger Thiele
Journal: European Journal of Heart Failure (2023)

Anaemia and iron deficiency (ID) are common comorbidities in cardiovascular patients and are associated with a poor clinical status, as well as a worse outcome in patients with heart failure and acute myocardial infarction (AMI). Nevertheless, data concerning the impact of anaemia and ID on clinical outcomes in patients with cardiogenic shock (CS) are scarce. This study aimed to assess the impact of anaemia and ID on clinical outcomes in patients with CS complicating AMI.
Retraction—Preventing dementia through correcting hearing: huge progress but more to do
Authors: None The Lancet Public Health Editors
Journal: The Lancet Public Health (2023)

In this Comment,1Livingston G Costafreda S Retracted—Preventing dementia through correcting hearing: huge progress but more to do.Lancet Public Health. 2023; 8: e319-e320Summary Full Text Full Text PDF PubMed Scopus (5) Google Scholar the authors cite and interpret data based on an Article we now know to be erroneous and which has now been retracted. In these circumstances, the UK Committee on Publication Ethics advises that the linked Comment should also be retracted to avoid any misunderstanding among readers. We are therefore retracting this Comment. RETRACTED: Preventing dementia through correcting hearing: huge progress but more to doWorldwide hearing loss is a major modifiable risk factor for dementia, with the largest effect in the population.1 A systematic review published in February, 2023, included 25 observational studies and six trials on the association of correcting hearing loss with hearing aids or cochlear implants and cognitive decline or dementia.2 The review included a meta-analysis of eight cohort studies with 126 903 participants and a follow-up of 2–25 years, and found that people with hearing loss who used hearing aids had an 19% lower risk of cognitive decline and a 17% lower risk of dementia, compared with those with uncorrected hearing loss. Full-Text PDF Open Access
Flow‐based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper
Authors: C. Mayorga, G. E. Çelik, M. Pascal, H. J. Hoffmann, B. Eberlein, M. J. Torres, K. Brockow, L. H. Garvey, A. Barbaud, R. Madrigal‐Burgaleta, J. C. Caubet, D. G. Ebo
Journal: Allergy (2023)

Abstract Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) “Basophil activation test in the evaluation of Drug Hypersensitivity Reactions” from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus‐based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug‐specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti‐inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory.
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
Authors: Aristotelis Bamias, Ian D Davis, Matthew D Galsky, José Á Arranz, Eiji Kikuchi, Enrique Grande, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Fabio A Schutz, Javier Puente, Jian-Ri Li, Stefano Panni, Mahmut Gumus, Mustafa Özgüroğlu, Sanjeev Mariathasan, Yekaterina Poloz, Fabiola Bene-Tchaleu, Chooi Lee, Sandrine Bernhard, Maria De Santis
Journal: The Lancet Oncology (2023)
Risk factors for cognitive impairment and dementia after stroke: a systematic review and meta-analysis
Authors: Jule Filler, Marios K Georgakis, Martin Dichgans
Journal: The Lancet Healthy Longevity (2023)

Cognitive impairment and dementia are highly prevalent among stroke survivors and represent a major burden for patients, carers, and health-care systems. We studied the risk factors for post-stroke cognitive impairment (PSCI) and dementia (PSD) beyond the well established risk factors of age and stroke severity.
CML and the WHO: Why?
Authors: Ellin Berman, Neil P. Shah, Michael Deininger, Jessica K. Altman, Maria Amaya, Kebede Begna, Ravi Bhatia, Onyee Chan, Robert Collins, Peter Curtin, Daniel J. DeAngelo, Michael Drazer, Lori Maness, Leland Metheny, Sanjay Mohan, Joseph Moore, Vivian Oehler, Keith Pratz, Iskra Pusic, Michal Rose, William Shomali, B. Douglas Smith, Michael Styler, Kendra Sweet, Moshe Talpaz, Tiffany Tanaka, Srinivas Tantravahi, Steven Tsai, Jennifer Vaughn, Jeanna Welborn, David Yang, Michael Mauro, Jorge Cortes, Jerald Radich, Brian Druker
Journal: Journal of Clinical Oncology (2023)

understanding of disease states, and without question, as our understanding of this disease increases, our classifications
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study
Authors: Arvid Engström, Viktor Wintzell, Mads Melbye, Henrik Svanström, Björn Eliasson, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Anders Hviid, Peter Ueda, Björn Pasternak
Journal: Hepatology (2023)

Background and Aims: Clinical trials suggest that glucagon-like peptide-1 (GLP-1) receptor agonists may have beneficial effects on NAFLD, but the impact on hard hepatic end points is unknown. We assessed the association between the use of GLP-1 receptor agonists and the risk of serious liver events in routine clinical practice. Approach and Results: Cohort study using data from nationwide registers in Sweden, Denmark, and Norway, 2007–2020, including 91,479 initiators of GLP-1 receptor agonists and 244,004 initiators of the active comparator, dipeptidyl peptidase-4 inhibitors, without a history of chronic liver disease other than NAFLD/NASH. The primary outcome was serious liver events: a composite of incident compensated and decompensated cirrhosis and HCC. Secondary outcomes were the individual components of the primary outcome. Cox regression was used to estimate HRs, using propensity score weighting to control for confounding. Users of GLP-1 receptor agonists had 608 serious liver events (adjusted incidence rate: 16.9 events per 10,000 person-years), compared with 1770 events among users of dipeptidyl peptidase-4 inhibitors (19.2 events per 10,000 person-years). The adjusted HR was 0.85 (95% CI: 0.75 to 0.97), and the rate difference was −2.1 (−4.4 to 0.1) events per 10,000 person-years. In secondary outcome analyses, the adjusted HR was 0.85 (0.75 to 0.97) for compensated and decompensated cirrhosis and 1.05 (0.80 to 1.39) for HCC. Conclusions: The use of GLP-1 receptor agonists was associated with a significantly reduced risk of serious liver events, driven by a reduction of compensated and decompensated cirrhosis.
Early identification of delayed wound healing in complex diabetic foot ulcers treated with a dermal regeneration template: a novel clinical target and its risk factors
Authors: Ting-Yu Tai, Kuan-Jie Lin, Hao-Yun Chang, Yi-Chun Wu, Ching-Uen Huang, Xin-Yi Lin, Feng-Chou Tsai, Ching-Sung Tsai, Yu-Han Chen, Fu-Yu Wang, Shun-Cheng Chang
Journal: International Journal of Surgery (2023)

Background: The dermal regeneration template (DRT), a tissue-engineered skin substitute composing a permanent dermal matrix and an upper temporary silicone layer that serves as the epidermis, has demonstrated efficacy in treating uncomplicated diabetic foot ulcers (DFUs). Our institution has obtained good outcomes with DRT in patients with more complicated DFUs. Because of its chronicity, we are working to identify a clinical target that anticipates delayed healing early in the treatment in addition to determining the risk factors linked to this endpoint to increase prevention. Materials and methods: This retrospective single-center study analyzed patients with DFUs who underwent wound reconstruction using DRT between 2016 and 2021. The patients were categorized into poor or good graft-take groups based on their DRT status on the 21 st day after the application. Their relationship with complete healing rate at day 180 was analyzed. Variables were collected for risk factors for poor graft take at day 21. Independent risk factors were identified after multivariable analysis. The causes of poor graft take were also reported. Results: This study examined 80 patients (38 and 42 patients in the poor and good graft-take groups, respectively). On day 180, the complete healing rate was 86.3% overall, but the poor graft-take group had a significantly lower complete healing rate (76.3% vs. 95.2%, P = 0.021) than the good graft-take group. Our analysis identified four independent risk factors: transcutaneous oxygen pressure &lt; 30 mmHg (odds ratio, 154.14), off-loading device usage (0.03), diabetic neuropathy (6.51), and toe wound (0.20). The most frequent cause of poor graft take was infection (44.7%), followed by vascular compromise (21.1%) and hematoma (15.8%). Conclusion: Our study introduces the novel concept of poor graft take at day 21 associated with delayed wound healing. Four independent risk factors were identified, which allows physicians to arrange interventions to mitigate their effects or select patients more precisely. DRT represents a viable alternative to address DFUs, even in complicated wounds. A subsequent split-thickness skin graft is not always necessary to achieve complete healing.
Impact of intravenous dexmedetomidine on postoperative gastrointestinal function recovery: an updated meta-analysis
Authors: Yi-Chen Lai, Wei-Ting Wang, Kuo-Chuan Hung, Jen-Yin Chen, Jheng-Yan Wu, Ying-Jen Chang, Chien-Ming Lin, I-Wen Chen
Journal: International Journal of Surgery (2023)

Background: Postoperative ileus (POI) is a complication that may occur after abdominal or nonabdominal surgery. Intravenous dexmedetomidine (Dex) has been reported to accelerate postoperative gastrointestinal function recovery; however, updated evidence is required to confirm its robustness. Methods: To identify randomized controlled trials examining the effects of perioperative intravenous Dex on gastrointestinal function recovery in patients undergoing noncardiac surgery, databases including MEDLINE, EMBASE, Google Scholar, and Cochrane Library were searched on August 2023. The primary outcome was time to first flatus. Secondary outcomes included time to oral intake and defecation as well as postoperative pain scores, postoperative nausea/vomiting (PONV), risk of hemodynamic instability, and length of hospital stay (LOS). To confirm its robustness, subgroup analyses and trial sequential analysis were performed. Results: The meta-analysis of 22 randomized controlled trials with 2566 patients showed that Dex significantly reduced the time to flatus [mean difference (MD):−7.19 h, P &lt;0.00001), time to oral intake (MD: −6.44 h, P =0.001), time to defecation (MD:−13.84 h, P =0.008), LOS (MD:−1.08 days, P &lt;0.0001), and PONV risk (risk ratio: 0.61, P &lt;0.00001) without differences in hemodynamic stability and pain severity compared with the control group. Trial sequential analysis supported sufficient evidence favoring Dex for accelerating bowel function. Subgroup analyses confirmed the positive impact of Dex on the time to flatus across different surgical categories and sexes. However, this benefit has not been observed in studies conducted in regions outside China. Conclusions: Perioperative intravenous Dex may enhance postoperative gastrointestinal function recovery and reduce LOS, thereby validating its use in patients for whom postoperative ileus is a significant concern.
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study
Authors: Shirley D’Sa, Josephine M. I. Vos, Wilma Barcellini, Marek Wardęcki, Laurent Perrin, Graham Barker, Moshe Zilberstein, Michael Storek, Timothy Chow, Alexander Röth
Journal: Blood (2023)

Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by complement pathway-mediated hemolysis. Riliprubart (SAR445088, BIVV020), a second-generation classical complement inhibitor, is a humanized monoclonal antibody that selectively inhibits only the activated form of C1s. This Phase 1b study evaluated the safety, tolerability, and effect on hemolysis of riliprubart in adult patients with cold agglutinin disease. On day 1, 12 patients received a single IV dose of either 30 mg/kg (n = 6) or 15 mg/kg (n = 6) of riliprubart and were subsequently followed for 15 weeks. Riliprubart was generally well tolerated; there were no treatment-emergent serious adverse events, or treatment-emergent adverse events leading to death or permanent study discontinuation. There were no reports of serious infections, encapsulated bacterial infections including meningococcal infections, hypersensitivity, or thromboembolic events. Rapid improvements in hemoglobin (day 5) and bilirubin (day 1) were observed in both treatment cohorts. Mean hemoglobin levels were maintained at >11.0 g/dL from day 29 and mean levels of bilirubin were normalized by day 29; both responses were maintained throughout the study. Improvements in clinical markers closely correlated with a sustained reduction in the 50% hemolytic complement (CH50) throughout the study. Mean C4 levels, an in vivo marker of treatment activity, increased 1 week after treatment with either dose of riliprubart and were sustained throughout the study. In conclusion, a single IV dose of riliprubart was well tolerated, and led to rapid classical complement inhibition, control of hemolysis, and improvement in anemia, all of which were sustained over 15 weeks. This trial was registered at www.ClinicalTrials.gov as #NCT04269551.
Prevalence and patterns of multimorbidity in China during 2002–2022: A systematic review and meta-analysis
Authors: Yaoda Hu, Zixing Wang, Huijing He, Li Pan, Ji Tu, Guangliang Shan
Journal: Ageing Research Reviews (2023)

Multimorbidity is common, particularly among elderly people. Restructuring health service systems to better manage this public health issue requires knowledge regarding disease prevalence and patterns. We quantified the epidemiology characteristics of multimorbidity among adults in China to inform policy-making and resource allocation.
Precision Oncology: 2023 in Review
Authors: Yonina R. Murciano-Goroff, Sarah P. Suehnholz, Alexander Drilon, Debyani Chakravarty
Journal: Cancer Discovery (2023)

Summary: This article presents a review of recent major advances in precision oncology and the future implications of these advances, specifying the iterative progress achieved from the end of 2022 through 2023. We discuss the different classes of precision oncology drugs and associated biomarkers as well as the improvements in clinical trial design that have enabled the efficient testing of these drugs.
A commentary on ‘Toxicities associated with immune checkpoint inhibitors: a systematic study’
Authors: Yuan Liu, Letian Qiao, Han Liu
Journal: International Journal of Surgery (2023)

aDepartment of Pharmacy, First People's Hospital of Shangqiu, Henan, 476100, PR China bChinese Preventive Medicine Association, Beijing, 100021, PR China Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: E-mail address: [email protected] (H. Liu) This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Comparison of short-term outcomes of robotic-assisted radical colon cancer surgery using the Kangduo Surgical Robotic System and the Da Vinci Si Robotic System: a prospective cohort study
Authors: Yunxiao Liu, Yuliuming Wang, Chunlin Wang, Xin Wang, Xin Zhang, Yihaoran Yang, Zhengqiang Wei, Yi Xiao, Guiyu Wang
Journal: International Journal of Surgery (2023)

Robotic surgery has been a revolution for colon cancer (CC) patients, with the increasing availability of different competitive robotic systems, but evidence of relevant oncologic outcomes is indeed scarce. Our goal was to compare the surgical quality and short-term oncologic outcomes of the Kangduo Surgical Robotic System and the da Vinci Si Robotic System in patients with CC.
A commentary on ‘Autologous blood transfusion reduces the requirement for perioperative allogenic blood transfusion in patients undergoing major hepatopancreatobiliary surgery: a retrospective cohort study’
Authors: Yongchao He, Shaoping Yu, Xiaoyi Yuan, Feng Duan, Jing Liu
Journal: International Journal of Surgery (2023)

aOperating Room,Yantai Yuhuangding Hospital,Yantai,Shandong 264000,China bDepartment of Hepatobiliary Surgery,Yantai Yuhuangding Hospital,Yantai,Shandong 264000,China cSchool of Forensic Medicine and Medical Laboratory,Jining Medical University.Jinan,Shandong 250000,China Co-authors:Yongchao He and Shaoping Yu equally contributed to the article. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Operating Room,Yantai Yuhuangding Hospital,Yantai,Shandong 264000,China. Email: [email protected] (J. Liu). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Harmonizing pain: the melodic pathway to hypoalgesia through emotional music responses – correspondence
Authors: Tooba Ali, Zainab Nazir, Muhammad Talha, Ashna Habib, Fatima A. Raza, Md Ariful Haque
Journal: International Journal of Surgery (2023)

Ali, Tooba MBBS; Nazir, Zainab MBBS; Talha, Muhammad MBBS; Habib, Ashna MBBS; A Raza, Fatima MBBS; Haque, Md Ariful MBBS; MD; MPH Author Information
Pancreatic ductal adenocarcinoma staging: A narrative review of radiologic techniques and advances
Authors: Linda C. Chu, Elliot K. Fishman
Journal: International Journal of Surgery (2023)

Radiology plays an important role in the initial diagnosis and staging of patients with pancreatic ductal adenocarcinoma (PDAC). CT is the preferred modality over MRI, due to wider availability, greater consistency in image quality, and lower cost. MRI and PET/CT are usually reserved as problem-solving tools in select patients. The National Comprehensive Cancer Network (NCCN) guidelines define resectability criteria based on tumor involvement of the arteries and veins, and triage patients into resectable, borderline resectable, locally advanced, and metastatic categories. Patients with resectable disease are eligible for upfront surgical resection, while patients with high-stage disease are treated with neoadjuvant chemotherapy and/or radiation therapy with hopes of downstaging the disease. The accuracy of staging critically depends on imaging technique and the experience of the radiologists. Several challenges in accurate preoperative staging include prediction of lymph node metastases, detection of subtle liver and peritoneal metastases, and disease restaging following neoadjuvant therapy. Artificial intelligence (AI) has the potential to function as "second readers" to improve upon the radiologists' detection of small early-stage tumors, which can shift more patients toward surgical resection of potentially curable cancer. AI may also provide imaging biomarkers that can predict disease recurrence and patient survival after pancreatic resection and assist in selection of patients most likely to benefit from surgery thus improving patient outcomes.